Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Proton Pump Inhibitor

Therapeutic area intelligence for Proton Pump Inhibitor with 9 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 9
Catalysts: 0
Companies: 1

Companies

Marksans Pharma →

Assets

Esomeprazole →

Shuangcheng →

Recent signals(9)

RegulatoryAugust 9, 2026

FDA Accepts Supplement Application for Esomeprazole Magnesium by Marksans Pharma

The FDA has accepted a supplemental application for esomeprazole magnesium submitted by Marksans Pharma.

August 1, 2026

FDA Submission Update for Omeprazole by Dr. Reddy's

Reddy's has submitted a supplemental application for Omeprazole (ANDA207740) with an unknown review priority.

RegulatoryJuly 28, 2026

FDA Grants Approval for Pantoprazole Sodium ANDA219973

The FDA has granted approval for the ANDA219973 application for Pantoprazole Sodium submitted by Shuangcheng.

StrategyJuly 19, 2026

FDA Accepts ANDA for Esomeprazole Magnesium by Marksans Pharma

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Esomeprazole Magnesium submitted by Marksans Pharma.

StrategyJuly 11, 2026

FDA Approval Update for Omeprazole ANDA207740 by Dr. Reddy's

Reddy's has submitted an Abbreviated New Drug Application (ANDA) for Omeprazole, currently under review.

RegulatoryJuly 8, 2026

FDA Accepts Supplement Application for Omeprazole Magnesium by Marksans Pharma

The FDA has accepted a supplement application (ANDA218829) for Omeprazole Magnesium submitted by Marksans Pharma.

StrategyJuly 5, 2026

FDA Grants Approval for Pantoprazole Sodium ANDA219973

The FDA has granted approval for ANDA219973, a generic version of Pantoprazole Sodium, submitted by Shuangcheng.

RegulatoryJune 23, 2026

FDA Grants AP Status for Pantoprazole Sodium Supplement by Meitheal

The FDA has granted Abbreviated Approval (AP) status for the Pantoprazole Sodium supplement submitted by Meitheal.

RegulatoryJune 22, 2026

FDA Grants Approval for Rabeprazole Sodium ANDA204237

The FDA has granted approval for ANDA204237, a supplemental application for Rabeprazole Sodium submitted by Rubicon Research.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.